FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2240720125> ?p ?o ?g. }

• W2240720125 endingPage "3185" @default.
• W2240720125 startingPage "3185" @default.
• W2240720125 abstract "3185 Background: 1,25 dehydroxyvitamin D (calcitriol) has anticancer effects by stimulating cell differentiation and inhibiting proliferation and angiogenesis. Its major drawback is stimulation of osteoclasts with liberation of cancer growth factors from bone and hypercalcemia. Aminobisphosphonates inhibit osteoclasts and correct hypercalcemia of malignancies. We reported bone healing with calcitriol + pamidronate in 2 multiple myeloma patients (pts) (AmJMedSci, 1999). We are reporting ongoing findings during a 12 month (m) pilot trial with zoledronic acid (Z) + calcitriol (C) in 10 pts (5 women, 5 men), with bone metastases from various tumors (4 breast, 4 prostate, 2 myeloma). Methods: Patients on cancer therapy received Z, 4 mg i.v./m + C (Calcijex), 1 μg i.v., 2/week x 2 weeks, followed by C (Rocaltrol) 0.25 μg po/tid + Ca 1,500 mg/d. Chemistries, calciotropic factors, bone turnover markers, skeletal MRI and bone density by DEXA were determined at 1 - 3 m. Results: Two pts died of cancer in the first 2 m and 1 pt discontinued the protocol in the 11th m due to progression of cancer. Two pts completed 12 m of the study. Three pts completed 6 m and 2 pts, 3 m. Z + C were well tolerated. There was no severe hypercalcemia (>11.3 mg/dl) or hypercalciuria. Skeletal MRI at 3 m intervals showed no new lesions or progression of the lesions in 5 of 6 pts who had at least two MRI; two of them showed sclerosis suggesting healing of the lesions, and 1 pt showed progression of the lesions. Bone density increased in 5 of 5 pts at 6 m of treatment (hip 6.0%, lumbar spine 10.5%, whole body 2.6%). PTH fell in 7 of 7 pts by 62%. Serum C remained within the normal range in most pts and urinary NTX, a marker of bone resorption, fell in 6 of 6 pts by 60%. Conclusion: Ongoing data suggest: 1. Z + C were well tolerated. 2. Skeletal metastases did not progress in most pts and in 2 pts signs of bone healing were observed. 3. Bone density increased in multiple sites. 4. PTH and NTX fell by 60%. These results are encouraging and support the continuation and completion of this study. No significant financial relationships to disclose." @default.
• W2240720125 created "2016-06-24" @default.
• W2240720125 creator A5008565364 @default.
• W2240720125 creator A5072563567 @default.
• W2240720125 creator A5076063588 @default.
• W2240720125 date "2004-07-15" @default.
• W2240720125 modified "2023-10-14" @default.
• W2240720125 title "Zoledronic acid and calcitriol in malignancies with bone involvement. A pilot trial" @default.
• W2240720125 doi "https://doi.org/10.1200/jco.2004.22.90140.3185" @default.
• W2240720125 hasPublicationYear "2004" @default.
• W2240720125 type Work @default.
• W2240720125 sameAs 2240720125 @default.
• W2240720125 citedByCount "0" @default.
• W2240720125 crossrefType "journal-article" @default.
• W2240720125 hasAuthorship W2240720125A5008565364 @default.
• W2240720125 hasAuthorship W2240720125A5072563567 @default.
• W2240720125 hasAuthorship W2240720125A5076063588 @default.
• W2240720125 hasConcept C121608353 @default.
• W2240720125 hasConcept C124490489 @default.
• W2240720125 hasConcept C126322002 @default.
• W2240720125 hasConcept C126894567 @default.
• W2240720125 hasConcept C2776079296 @default.
• W2240720125 hasConcept C2776139714 @default.
• W2240720125 hasConcept C2776326535 @default.
• W2240720125 hasConcept C2776364478 @default.
• W2240720125 hasConcept C2780192828 @default.
• W2240720125 hasConcept C71924100 @default.
• W2240720125 hasConcept C90924648 @default.
• W2240720125 hasConceptScore W2240720125C121608353 @default.
• W2240720125 hasConceptScore W2240720125C124490489 @default.
• W2240720125 hasConceptScore W2240720125C126322002 @default.
• W2240720125 hasConceptScore W2240720125C126894567 @default.
• W2240720125 hasConceptScore W2240720125C2776079296 @default.
• W2240720125 hasConceptScore W2240720125C2776139714 @default.
• W2240720125 hasConceptScore W2240720125C2776326535 @default.
• W2240720125 hasConceptScore W2240720125C2776364478 @default.
• W2240720125 hasConceptScore W2240720125C2780192828 @default.
• W2240720125 hasConceptScore W2240720125C71924100 @default.
• W2240720125 hasConceptScore W2240720125C90924648 @default.
• W2240720125 hasIssue "14_suppl" @default.
• W2240720125 hasLocation W22407201251 @default.
• W2240720125 hasOpenAccess W2240720125 @default.
• W2240720125 hasPrimaryLocation W22407201251 @default.
• W2240720125 hasRelatedWork W2056541722 @default.
• W2240720125 hasRelatedWork W2368085886 @default.
• W2240720125 hasRelatedWork W2413364802 @default.
• W2240720125 hasRelatedWork W2469515091 @default.
• W2240720125 hasRelatedWork W3028895977 @default.
• W2240720125 hasRelatedWork W3031456473 @default.
• W2240720125 hasRelatedWork W3032254165 @default.
• W2240720125 hasRelatedWork W2476724097 @default.
• W2240720125 hasRelatedWork W2780491316 @default.
• W2240720125 hasRelatedWork W3139865262 @default.
• W2240720125 hasVolume "22" @default.
• W2240720125 isParatext "false" @default.
• W2240720125 isRetracted "false" @default.
• W2240720125 magId "2240720125" @default.
• W2240720125 workType "article" @default.